Recipharm AB - Strategic SWOT Analysis Review

Recipharm AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The analyst’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Recipharm AB (Recipharm) is a pharmaceutical Contract Development and Manufacturing Organisation (CDMO). It provides end-to-end services for the entire product lifecycle, from drug substance development to commercial manufacturing. The company specializes in both small molecules and biologics, offering services in various modalities, including RNA therapies, gene therapy, and biologics manufacturing. Recipharm also provides solutions for solid dosage forms, aseptic fill and finish, and specialized products such as ophthalmics and vaccines. The company operates a global network of facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

• Feb 05, 2025: Recipharm Expands Aseptic Filling Capabilities for Process Development, Pilot Scale and Clinical Supply
• Jan 13, 2025: ReciBioPharm Secures a Significant Grant to Advance RNA Manufacturing
• Nov 19, 2024: Recipharm’s full range Oral Solid Dosage (OSD) Capabilities Meet Growing Industry Demands
• Oct 03, 2024: Recipharm Strengthens Pharmaceutical Development Capabilities with Strategic Investments

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.